ACB — Aurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Fiscal Year 2026 Results:

  • Net revenue increased by 11% to CAD 321 million, exceeding guidance by CAD 8 million.
  • Adjusted gross margin improved to 64%.
  • Adjusted EBITDA rose 32% year-over-year to CAD 54 million.
  • Cash and cash equivalents stood at CAD 165 million with no debt.

• Q4 2026 Results:

  • Net revenue of CAD 84.8 million, a 10% increase year-over-year, driven by a 14% rise in global medical cannabis revenue.
  • Adjusted gross margin at 60%.
  • Adjusted EBITDA was CAD 9.2 million, consistent with guidance.
  • Adjusted net income decreased to CAD 5.6 million from CAD 16.3 million in the prior year.

2. Strategic Updates and Business Highlights:

• Aurora emphasized its leadership in the medical cannabis sector, particularly in Canada, Germany, Australia, and Poland.
• The company is exiting lower-margin Canadian consumer markets and divested its plant propagation business to focus on higher-margin medical cannabis.
• Acquired Safari Flower Company for CAD 26.5 million to enhance EU GMP capacity and support international growth.
• Expanded medical cannabis portfolio across multiple regions, including new product launches in Canada, Europe, Australia, and New Zealand.
• Significant investments in plant science are expected to yield higher potency and disease-resistant cultivars.

3. Forward Guidance and Outlook:

• For FY 2027, total net revenue is expected to decline, aligning more with FY 2025 results due to changes in Canadian medical reimbursement rates.
• Adjusted gross margins anticipated in the mid-to-high 50s, reflecting the exit from lower-margin businesses and continued international growth.
• Adjusted EBITDA is expected to vary quarterly, leading to lower annual figures compared to FY 2026.

4. Bad News, Challenges, or Points of Concern:

• The recent change in Canadian medical reimbursement rates, effective April 1, 2026, is projected to reduce revenue by approximately 30%, impacting adjusted gross margins.
• Increased competition and pricing pressures in international markets, particularly in Germany, where price compression is noted in the value segment.
• Adjusted SG&A expenses rose due to inflation-related labor costs and credit losses from customer insolvencies.
• The transition from consumer markets may lead to short-term revenue impacts despite long-term strategic benefits.

5. Notable Q&A Insights:

• Management acknowledged that the reimbursement rate change in Canada is the primary driver of expected revenue and margin declines.
• The acquisition of Safari Flower is seen as immediately accretive, with potential synergies expected as integration progresses.
• Discussions around the U.S. market highlighted potential opportunities for partnerships and research collaborations, contingent on regulatory changes.
• Management remains optimistic about the German market despite recent import declines, citing a strong regulatory framework and premium product demand.
• The company is cautious about entering the U.S. market until more regulatory clarity is achieved, emphasizing the importance of GMP standards in maintaining competitive advantages.

Overall, Aurora Cannabis demonstrated strong performance in FY 2026 but faces headwinds from regulatory changes and competitive pressures as it pivots towards a more focused medical cannabis strategy.